eisai.com — September 2026 traffic, keywords & AI visibility

eisai.com draws an estimated 42,100 visits a month from search engines. Effectively all of it is organic — about 42,100 visits from unpaid results. Spread across 5,113 ranking keywords, that averages roughly 8.2 organic visits per keyword.

On our AI visibility scale eisai.com earns 59 of 100 points, a grade D. It takes full marks for LLMS.txt. The biggest gap is SEO health, at 0 of 20 points (Not scanned yet), worth 20 points if closed. It also loses points on Crawlability (0/10), Company profile (19/25) and Structured data (0/5).

The llms.txt on eisai.com runs to 79 lines (5,562 characters) across 12 sections, last generated in May 2026. It introduces the site as "Eisai Co., Ltd.". It tells AI engines the business works in Pharmaceuticals, Biotechnology, Clinical Research and Healthcare Technology. It describes 5 products, including Aricept, Lenvima and Halaven. Services it lists include Clinical Trial Management, Drug Discovery Partnerships, Medical Education Programs and Patient Support Services. Technologies it mentions include Clinical Data Management Systems, Electronic Data Capture, Pharmacovigilance Platforms and Regulatory Submission Software. The keywords it claims start with "healthcare innovation", "pharmaceutical research", "clinical trials" and "patient care". It gives the company type as Public.

# Eisai Co., Ltd.

## About
Eisai is a global pharmaceutical company that has spent decades developing medicines aimed at improving the lives of patients with neurological disorders and cancer. Their work centers on discovering new treatments that address unmet medical needs, particularly in areas like Alzheimer's disease and oncology. The company maintains a strong presence in research and development, running clinical trials across multiple continents to test the safety and effectiveness of new drug candidates. Eisai partners with hospitals, research institutions, and healthcare providers to bring these innovations from the lab into real-world patient care. They emphasize a patient-centric approach, ensuring that their therapies consider quality of life alongside clinical outcomes. The company invests heavily in biotechnology platforms that allow them to explore novel mechanisms of action for treating complex diseases. Eisai also focuses on sustainability initiatives that reduce the environmental impact of their manufacturing and distribution processes. Their corporate responsibility programs extend to supporting communities in the regions where they operate, including health education and access to medicines for underserved populations. Eisai collaborates with other pharmaceutical firms and academic centers to accelerate drug discovery and share scientific knowledge. They ma

Google lists eisai.com for about 5,113 keywords, which together bring an estimated 42,100 organic visits a month.

Eisai Co., Ltd.'s company profile names https://www.pharmaceutical-technology.com, https://www.biopharma-reporter.com and https://www.fiercebiotech.com as competitors. Its own llms.txt adds https://www.healthcareitnews.com and https://www.drugdiscoverynews.com. Outside its market, the domains ranked closest to it in our worldwide ranking are planecde.com, nfid.org, hometutorsite.com and mfa.gov.ge.

https://www.pharmaceutical-technology.com

https://www.biopharma-reporter.com

https://www.fiercebiotech.com

https://www.healthcareitnews.com

https://www.drugdiscoverynews.com